RUFY4 deletion prevents pathological bone loss by blocking endo-lysosomal trafficking of osteoclasts

Abstract

Mature osteoclasts degrade bone matrix by exocytosis of active proteases from secretory lysosomes through a ruffled border. However, the molecular mechanisms underlying lysosomal trafficking and secretion in osteoclasts remain largely unknown. Here, we show with GeneChip analysis that RUN and FYVE domain-containing protein 4 (RUFY4) is strongly upregulated during osteoclastogenesis. Mice lacking Rufy4 exhibited a high trabecular bone mass phenotype with abnormalities in osteoclast function in vivo. Furthermore, deleting Rufy4 did not affect osteoclast differentiation, but inhibited bone-resorbing activity due to disruption in the acidic maturation of secondary lysosomes, their trafficking to the membrane, and their secretion of cathepsin K into the extracellular space. Mechanistically, RUFY4 promotes late endosome-lysosome fusion by acting as an adaptor protein between Rab7 on late endosomes and LAMP2 on primary lysosomes. Consequently, Rufy4-deficient mice were highly protected from lipopolysaccharide- and ovariectomy-induced bone loss. Thus, RUFY4 plays as a new regulator in osteoclast activity by mediating endo-lysosomal trafficking and have a potential to be specific target for therapies against bone-loss diseases such as osteoporosis.

References

1. Zaidi M.Skeletal remodeling in health and disease. Nat. Med. 13, 791-801 (2007).
2. Delaisse, J. M.et al.Re-thinking the bone remodeling cycle mechanism and the origin of bone loss. Bone 141, 115628 (2020).
3. Park, J. H., Lee, N. K. & Lee, S. Y. Current understanding of RANK signaling in osteoclast differentiation and maturation. Mol. Cells 40, 706-713 (2017).
4. Baron, R.et al.Polarized secretion of lysosomal enzymes: co-distribution of cation-independent mannose-6-phosphate receptors and lysosomal enzymes along the osteoclast exocytic pathway. J. Cell Biol. 106, 1863-1872 (1988).
5. Vaananen H. K., Zhao H., Mulari M.& Halleen, J. M. The cell biology of osteoclast function. J. Cell Sci. 113, 377-381 (2000).
6. Feng X.& Teitelbaum, S. L. Osteoclasts: new insights. Bone Res. 1, 11-26 (2013).
7. Mellman I.Endocytosis and molecular sorting. Annu. Rev. Cell Dev. Biol. 12, 575-625 (1996).
8. Andrews N. W.Regulated secretion of conventional lysosomes. Trends Cell Biol. 10, 316-321 (2000).
9. Dell'Angelica, E. C., Mullins, C., Caplan, S. & Bonifacino, J. S. Lysosome-related organelles. FASEB J. 14, 1265-1278 (2000).
10. Obino, D.et al. Vamp-7-dependent secretion at the immune synapse regulates antigen extraction and presentation in B-lymphocytes. Mol. Biol. Cell 28, 890-897 (2017).
11. Jung J., Jo H. W., Kwon H.& Jeong, N. Y. ATP release through lysosomal exocytosis from peripheral nerves: the effect of lysosomal exocytosis on peripheral nerve degeneration and regeneration after nerve injury. Biomed. Res. Int. 2014, 936891(2014).
12. Zhao, H. B.et al. Synaptotagmin VII regulates bone remodeling by modulating osteoclast and osteoblast secretion. Develop. Cell 14, 914-925 (2008).
13. Luzio, J. P., Pryor, P. R.& Bright, N. A. Lysosomes: fusion and function. Nat. Rev. Mol. Cell Biol. 8, 622-632 (2007).
14. Saftig P.& Klumperman, J. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat. Rev. Mol. Cell Biol. 10, 623-635 (2009).
15. Huotari J.& Helenius, A. Endosome maturation. Embo J. 30, 3481-3500 (2011).
16. Saffi G. T.& Botelho, R. J. Lysosome fission: planning for an exit. Trends Cell Biol. 29, 635-646 (2019).
17. van der Beek, J., Jonker, C., van der Welle, R., Liv, N. & Klumperman, J. CORVET, CHEVI and HOPS - multisubunit tethers of the endo-lysosomal system in health and disease. J. Cell Sci. 132, jcs189134 (2019).
18. Spang A.Membrane tethering complexes in the endosomal system. Front. Cell Dev. Biol. 4, 35(2016).
19. Baker, R. W.et al. A direct role for the Sec1/Munc18-family protein Vps33 as a template for SNARE assembly. Science 349, 1111-1114 (2015).
20. Terawaki S., Camosseto V., Pierre, P. & Gatti, E. RUFY4: immunity piggybacking on autophagy? Autophagy 12, 598-600 (2016).
21. Char R.& Pierre, P. The RUFYs, a family of effector proteins involved in intracellular trafficking and cytoskeleton dynamics. Front. Cell Develop. Biol. 8, 779(2020).
22. Terawaki, S.et al.RUN and FYVE domain-containing protein 4 enhances autophagy and lysosome tethering in response to Interleukin-4. J. Cell Biol. 210, 1133-1152 (2015).
23. Keren-Kaplan, T. et al. RUFY3 and RUFY4 are ARL8 effectors that promote coupling of endolysosomes to dynein-dynactin. Nat. Commun. 13, 1506(2022).
24. Zhao H. B.,Laitala-Leinonen, T., Parikka, V. & Vaananen, H. K. Downregulation of small GTPase Rab7 impairs osteoclast polarization and bone resorption. J. Biol. Chem. 276, 39295-39302 (2001).
25. Takayanagi, H.et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889-901 (2002).
26. Boyce B. F., Xiu Y., Li J., Xing L.& Yao, Z. NF-kappaB-mediated regulation of osteoclastogenesis. Endocrinol. Metab. (Seoul) 30, 35-44 (2015).
27. Xie, H.et al.PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat. Med. 20, 1270-1278 (2014).
28. Martin T. J.& Sims, N. A. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med. 11, 76-81 (2005).
29. Batsir, S., Geiger, B. & Kam, Z. Dynamics of the sealing zone in cultured osteoclasts. Cytoskeleton 74, 72-81 (2017).
30. Destaing O., Saltel F., Geminard J. C., Jurdic, P. & Bard, F. Podosomes display actin turnover and dynamic self-organization in osteoclasts expressing actingreen fluorescent protein. Mol. Biol. Cell 14, 407-416 (2003).
31. Wang T. L., Ming Z., Wu X. C.& Hong, W. J. Rab7: role of its protein interaction cascades in endo-lysosomal traffic. Cell. Signal. 23, 516-521 (2011).
32. Poteryaev D., Datta S., Ackema K., Zerial, M. & Spang, A. Identification of the switch in early-to-late endosome transition. Cell 141, 497-508 (2010).
33. Eskelinen E. L.Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. Mol. Aspects Med. 27, 495-502 (2006).
34. Sardiello, M.et al. A gene network regulating lysosomal biogenesis and function. Science 325, 473-477 (2009).
35. Song, T. T.et al.The important role of TFEB in autophagy-lysosomal pathway and autophagy-related diseases: a systematic review. Eur. Rev. Med. Pharmacol. Sci. 25, 1641-1649 (2021).
36. Ng P. Y.,Brigitte Patricia Ribet, A. & Pavlos, N. J. Membrane trafficking in osteoclasts and implications for osteoporosis. Biochem. Soc. Trans. 47, 639-650 (2019).
37. Hayakawa A., Hayes S., Leonard D., Lambright D.& Corvera, S. Evolutionarily conserved structural and functional roles of the FYVE domain. Biochem. Soc. Symp. 74, 95-105 (2007).
38. Pankiv, S.et al.FYCO1 is a Rab7 effector that binds to LC3 and PI3P to mediate microtubule plus end-directed vesicle transport. J. Cell Biol. 188, 253-269 (2010).
39. Turk, B., Turk, D.& Turk, V. Lysosomal cysteine proteases: more than scavengers. Bba-Protein Struct. M. 1477, 98-111 (2000).
40. Costa A. G., Cusano N. E., Silva B. C., Cremers S.& Bilezikian, J. P. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat. Rev. Rheumatol. 7, 447-456 (2011).
41. Battaglino R. A., Jha P., Sultana F., Liu W.& Morse, L. R. FKBP12: a partner of Snx10 required for vesicular trafficking in osteoclasts. J. Cell Biochem. 120, 13321-13329 (2019).
42. Sultana, F.et al.Snx10 and PIKfyve are required for lysosome formation in osteoclasts. J. Cell Biochem. 121, 2927-2937 (2020).
43. Li, M.et al. Gasdermin D maintains bone mass by rewiring the endo-lysosomal pathway of osteoclastic bone resorption. Dev. Cell 57, 2365-2380.e2368 (2022).
44. Char, R.et al.RUFY3 regulates endolysosomes perinuclear positioning, antigen presentation and migration in activated phagocytes. Nat. Commun. 14, 4290(2023).
45. Yamamoto, H.et al. Functional cross-talk between Rab14 and Rab4 through a dual effector, RUFY1/Rabip4. Mol. Biol. Cell 21, 2746-2755 (2010).
46. Fouraux, M. A.et al. Rabip4' is an effector of rab5 and rab4 and regulates transport through early endosomes. Mol. Biol. Cell 15, 611-624 (2004).
47. Cormont M., Mari M., Galmiche A., Hofman, P. & Le Marchand-Brustel, Y. A FYVEfinger- containing protein, Rabip4, is a Rab4 effector involved in early endosomal traffic. Proc. Natl. Acad. Sci. USA 98,1637-1642 (2001).
48. Fukuda, M. & Itoh, T. Direct link between Atg protein and small GTPase Rab: Atg16L functions as a potential Rab33 effector in mammals. Autophagy 4, 824-826 (2008).
49. Fukuda M., Kobayashi H., Ishibashi K.& Ohbayashi, N. Genome-wide investigation of the Rab binding activity of RUN domains: development of a novel tool that specifically traps GTP-Rab35. Cell Struct. Funct. 36, 155-170 (2011).
50. Coppola, V.et al. The autophagic protein FYCO1 controls TNFRSF10/TRAIL receptor induced apoptosis and is inactivated by CASP8 (caspase 8). Autophagy 19, 2733-2751 (2023).
51. Zhao, H., Ettala, O.& Vaananen, H. K. Intracellular membrane trafficking pathways in bone-resorbing osteoclasts revealed by cloning and subcellular localization studies of small GTP-binding rab proteins. Biochem. Biophys. Res. Commun. 293, 1060-1065 (2002).
52. Roy M.& Roux, S. Rab GTPases in osteoclastic bone resorption and autophagy. Int. J. Mol. Sci. 21, 7655(2020).
53. Taylor, A.et al. Impaired prenylation of Rab GTPases in the gunmetal mouse causes defects in bone cell function. Small GTPases 2, 131-142 (2011).
54. DeSelm, C. J.et al. Autophagy proteins regulate the secretory component of osteoclastic bone resorption. Dev. Cell 21, 966-974 (2011).
55. Rodan, G. A. & Martin, T. J. Therapeutic approaches to bone diseases. Science 289, 1508-1514 (2000).
56. Compston, J. E., McClung, M. R. & Leslie, W. D. Osteoporosis. Lancet 393, 364-376 (2019).
57. Tu, K. N.et al. Osteoporosis: a review of treatment options. P T 43, 92-104 (2018).
58. Khosla, S. & Hopbauer, L. C. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endo 5, 898-907 (2017).
59. Matsuo K.& Irie, N. Osteoclast-osteoblast communication. Arch. Biochem. Biophys. 473, 201-209 (2008).
60. Cao X.Targeting osteoclast-osteoblast communication. Nat. Med. 17, 1344-1346 (2011).
61. Maraka S.& Kennel, K. A. Bisphosphonates for the prevention and treatment of osteoporosis. Bmj-Brit Med. J. 351, h3783(2015).
62. Pawson, T. & Scott, J. D. Signaling through scaffold, anchoring,adaptor proteins. Science 278, 2075-2080 (1997).
63. Khor, E. C.et al.Loss of protein kinase C-delta protects against LPS-induced osteolysis owing to an intrinsic defect in osteoclastic bone resorption. PLoS One 8, e70815 (2013).
64. Li, S.et al.Conditional knockout of PKC-delta in osteoclasts favors bone mass accrual in males due to decreased osteoclast function. Front. Cell Dev. Biol. 8, 450(2020).
65. Ye, S.et al.LIS1 regulates osteoclast formation and function through its interactions with dynein/dynactin and Plekhm1. PLoS One 6, e27285 (2011).
66. Ng, P. Y.et al.Disruption of the dynein-dynactin complex unveils motor-specific functions in osteoclast formation and bone resorption. J. Bone Miner. Res. 28, 119-134 (2013).
67. Fujiwara, T.et al.PLEKHM1/DEF8/RAB7 complex regulates lysosome positioning and bone homeostasis. JCI Insight 1, e86330 (2016).
68. Suda T., Jimi E., Nakamura I.& Takahashi, N. Role of 1 alpha,25-dihydroxyvitamin D3 in osteoclast differentiation and function. Methods Enzymol. 282, 223-235 (1997).
69. Zhu, H.et al.A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone. Nat. Protoc. 5, 550-560 (2010).
70. Son, H. S.et al. Benzydamine inhibits osteoclast differentiation and bone resorption via down-regulation of interleukin-1 beta expression. Acta Pharm. Sin. B 10, 462-474 (2020).
71. Yoon, K.et al.TRAF6 deficiency promotes TNF-induced cell death through inactivation of GSK3 beta. Cell Death Differ. 15, 730-738 (2008).
72. Kim, M.et al.Tetraspanin 7 regulates osteoclast function through association with the RANK/αvβ3 integrin complex. J. Cell Physiol. 237, 846-855 (2022).

Funding

Soo Young Lee ([e-mail])